REVIEW ARTICLE

Supportive Care in Cancer

, Volume 5, Issue 5, pp 358-364

First online:

Controversies in new antibiotic therapy for ambulatory patients

  • V. SundararajanAffiliated withAmbulatory and Supportive Care Oncology Research Program (ASCORP), The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
  • , Edward B. RubensteinAffiliated withAmbulatory and Supportive Care Oncology Research Program (ASCORP), The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
  • , Kenneth V. I. RolstonAffiliated withAmbulatory and Supportive Care Oncology Research Program (ASCORP), The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
  • , Linda S. EltingAffiliated withAmbulatory and Supportive Care Oncology Research Program (ASCORP), The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

 The care of the febrile neutropenic patient has undergone a shift in the last 10 years with the realization that neutropenic patients presenting with fever do not constitute a homogeneous group. Strategies of risk assessment have allowed the testing of novel therapies including oupatient treatment with oral and intravenous antibiotics, either in combination regimens or as monotherapy; the addition of growth factors to hasten the return of the absolute neutrophil count; and the possibility of self-initiation of antibiotics by cancer patients when they develop fever. The clinical trials data regarding these new approaches will be reviewed, and areas requiring further research will be discussed.

Key words Neutropenia Fever Antibiotics Clinical trials